Prevention of myocardial fibrosis by  N-acetyl-seryl-aspartyl-lysyl-proline  in diabetic rats.
Castoldi
Giovanna
G
Clinica Nefrologica, Az Ospedaliera San Gerardo, 20052 Monza, Italy. giovanna.castoldi@unimib.it
di Gioia
Cira R T
CR
Bombardi
Camila
C
Perego
Carla
C
Perego
Lucia
L
Mancini
Massimiliano
M
Leopizzi
Martina
M
Corradi
Barbara
B
Perlini
Stefano
S
Zerbini
Gianpaolo
G
Stella
Andrea
A
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000818:Animals; D009202:Cardiomyopathies / Q000517:prevention & control; D048909:Diabetes Complications / Q000517:prevention & control*; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D005355:Fibrosis; D006352:Heart Ventricles / Q000187:drug effects / Q000473:pathology*; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage; D008297:Male; D009206:Myocardium / Q000473:pathology*; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D017257:Ramipril / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D051785:Smad Proteins / Q000187:drug effects / Q000378:metabolism; D053773:Transforming Growth Factor beta1 / Q000187:drug effects / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D009842:Oligopeptides; D051785:Smad Proteins; D053773:Transforming Growth Factor beta1; C058504:goralatide; D017257:Ramipril